Research on correlation between CYP2C19 gene polymorphism and clopidogrel curative effect in patients with coronary heart disease
10.3969/j.issn.1673-4130.2017.04.022
- VernacularTitle:CYP2C19基因多态性与冠心病患者氯吡格雷疗效的相关性研究
- Author:
Lin QI
;
Hui QIAO
;
Jingxian HAN
;
Shiwu LIU
;
Yiqiang YUAN
- Keywords:
CYP2C19 gene polymorphism;
coronary heart disease;
clopidogrel;
clinical analysis
- From:
International Journal of Laboratory Medicine
2017;38(4):488-489,492
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze and investigate the correlation between the CYP2C19 gene polymorphism and clopidogrel cura-tive effect in the patients with coronary heart disease (CHD) to provide valuable reference information for the future clinical work. Methods A total of 128 cases of CHD undergoing PCI in our hospital from January 2015 to January 2016 were selected as the re-search subjects.All of them were treated with clopidogrel ,the loading dose was 300mg ,and the maintenance dose was 75mg.The subjects were divided into the clopidogrel resistance group and response group.The drug-metabolizing CYP2C19 genotype was com-pared between the two groups and the effect of CYP2C19 genotype on the clopidogrel response was observed.Results Among the subjects ,27 cases were clopidogrel resistance.A total of 16 cases of CYP2C19 slow metabolic gene carriers were detected.There was statistically significant difference between the patients with chronic metabolic genotype VASP-PRI with fast metabolic geno-type and intermediate metabolic genotype(P<0.05).The incidence rate of adverse end point events had statistical difference be-tween the clopidogrel resistance group and clopidogrel response group(P<0.05).Conclusion In the risk factors of clopidogrel re-sistance ,slow metabolism CYP2C19 genotype and clopidogrel resistance will increase the risk of clinical adverse endpoint events oc-currence ,clinic should give adequate attention.
